newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

  • IGC Pharma received U.S. Patent No. 12,491,200 from the USPTO for a microdose-based cannabinoid treatment targeting stuttering & Tourette's Syndrome.
  • The patent covers proprietary methods using ultra-low doses of THC alone or combined with CBD to modulate neural circuits involved in vocal disruptions & involuntary motor symptoms.
  • This intellectual property expands IGC Pharma's portfolio beyond its primary focus on Alzheimer's disease.
  • The microdosing approach aims to stabilize neural activity & reduce hyperexcitability while maintaining a favorable safety profile with minimal psychoactive effects.
  • The new patent complements the company's lead asset IGC-AD1, which is currently in the CALMA Phase 2 trial for agitation in Alzheimer's dementia.
  • CEO Ram Mukunda stated the issuance strengthens IGC's leadership in cannabinoid-based neurological therapeutics & diversifies its pipeline of synthetic & small-molecule assets.
  • IGC Pharma utilizes AI to accelerate drug discovery & optimize clinical trials for its neurodegeneration & metabolic disorder programs.
  • The press release includes forward-looking statements subject to risks regarding commercialization, regulatory approval, AI functionality, & general economic conditions.